# GC Therapeutics

> Cell-therapy biotech using George Church–originated iPSC programming platform TFome.

## Why it is interesting

GC Therapeutics targets scalable off-the-shelf cell therapies; a16z Bio + Health joined Pear VC in its $65M Series A launch round.

## Profile

- **Stage:** series-a
- **Status:** private
- **Industries:** biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Series A (2024): $65M led by Cormorant Asset Management with a16z Bio + Health (/fund/andreessen-horowitz) and Pear VC (/fund/pear-vc) (BusinessWire)
- TFome platform originated from George Church's lab at Harvard; targets scalable off-the-shelf iPSC cell therapies

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz
- https://venturecapitaltracker.com/fund/pear-vc

## Related articles

- https://venturecapitaltracker.com/2026-a16z-hot-portfolio-companies

---
Source: https://venturecapitaltracker.com/startup/gc-therapeutics